In the current study, we show that PP2A activation resulted in decreased expression of the MYCN protein, independent of the MYCN amplification status of the tumor cells, suggesting a potential mechanism behind these compounds decreasing the malignant neuroblastoma phenotype and a potential therapeutic to target MYCN. Here, PTPA is linked to neuroblastoma.